Abstract:Cyclic nucleotide phosphodiesterase (PDE) enzymes catalyze the hydrolysis and inactivation of the cyclic nucleotides cyclic adenosine monophosphate and cyclic guanosine monophosphate, which act as intracellular second messengers for many signal transduction pathways in the central nervous system. Several classes of PDE enzymes with specific tissue distributions and cyclic nucleotide selectivity are highly expressed in brain regions involved in cognitive and motor functions, which are known to be implicated in neurodegenerative diseases, such as Parkinson's disease and Huntington's disease. The indication that PDEs are intimately involved in the pathophysiology of different movement disorders further stems from recent discoveries that mutations in genes encoding different PDEs, including PDE2A, PDE8B, and PDE10A, are responsible for rare forms of monogenic parkinsonism and chorea. We here aim to provide a translational overview of the preclinical and clinical data on PDEs, the role of which is emerging in the field of movement disorders, offering a novel venue for a better understanding of their pathophysiology. Modulating cyclic nucleotide signaling, by either acting on their synthesis or on their degradation, represents a promising area for development of novel therapeutic approaches. The study of PDE mutations linked to monogenic movement disorders offers the opportunity of better understanding the role of PDEs in disease pathogenesis, a necessary step to successfully benefit the treatment of both hyperkinetic and hypokinetic movement disorders. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Phosphodiesterases: Evolving Concepts and Implications for Human Therapeutics

Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

Phosphodiesterases in heart and vessels- From Physiology to Diseases

Phosphodiesterase in heart and vessels: from physiology to diseases.

Phosphodiesterase 7 as a therapeutic target - Where are we now?

Synthetic approaches and clinical application of representative small-molecule inhibitors of phosphodiesterase

Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health

Inhibitors of Phosphodiesterase As Cancer Therapeutics.

Review on Pharmcology of Phosphodiesterases Related Diseases

An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential

Protein-Protein Interactions of Phosphodiesterases

Role of Phosphodiesterases in Biology and Pathology 2.0

The Emerging Role of Phosphodiesterases in Movement Disorders

Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery

Research Progress of Phosphodiesterase Inhibitors in Inflammatory Bowel Disease Treatment.

Advances In The Development Of Phosphodiesterase-4 Inhibitors

Phosphodiesterase 2 and Its Isoform A as Therapeutic Targets in the Central Nervous System Disorders

Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)

An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors